This is the authors' abstract. We don't add key points for this paper.
Patients with pathogenic variants in the C-propeptide region of COL1A1/A2 and BMP1 appear to have a high bone mass phenotype with increased sensitivity to bisphosphonate therapy. It is important to closely monitor patients with these genotypes to assess their response to therapy and tailor their treatment regime accordingly.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Campanini et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: